# FUJIFILM Biotechnologies

> FUJIFILM Biotechnologies develops manufacturing processes and produces biologics, vaccines and advanced therapies for pharmaceutical and biotechnology companies. Its kojoX network standardizes facilities, equipment and operating systems across sites, with customers including Regeneron, Johnson & Johnson and argenx. Formerly branded FUJIFILM Diosynth Biotechnologies, it belongs to FUJIFILM Corporation and employs over 5,000 people.

- **Founded:** 2011
- **Headquarters:** Morrisville, United States
- **Products:** Biologics contract development and manufacturing, ApolloX, Paveway PLUS, Advanced therapies, Drug product and finished goods
- **Notable:** Opened the first phase of Holly Springs in September 2025 with eight 20,000-liter mammalian bioreactors., Signed the Regeneron manufacturing agreement worth more than $3 billion over ten years., Selected for the FDA PreCheck Pilot Program in July 2026.

## Products & services

- **Biologics contract development and manufacturing** — Mammalian and insect cell culture, microbial fermentation, process and analytical development, and clinical and commercial manufacturing.
- **ApolloX** — CHO-based cell line development for antibodies and other recombinant proteins; company reports research cell bank generation in as little as 10 weeks.
- **Paveway PLUS** — E. coli strain development and expression workflows for therapeutic proteins, including antibiotic-free fermentation approaches.
- **Advanced therapies** — Process development, analytical services and cGMP manufacturing for cell and gene therapies.
- **Drug product and finished goods** — Fill-finish and packaging services; availability and timing vary by site. July 2026 guidance places Holly Springs drug product line addition in early 2027, followed by finished goods.
- **CMC services** — Cell banking, formulation, characterization, comparability, method validation, stability and process characterization.
- **ShunzymeX** — Purification technology developed with the University of Edinburgh, using an engineered protease for scarless affinity-tag removal.

## Achievements

- Opened the first phase of Holly Springs in September 2025 with eight 20,000-liter mammalian bioreactors.
- Signed the Regeneron manufacturing agreement worth more than $3 billion over ten years.
- Selected for the FDA PreCheck Pilot Program in July 2026.
- Reported over 5,000 employees in August 2026.

## Latest updates

- **2026-08** — Maja Pedersen appointed president in addition to COO; Lars Petersen moved from president and CEO to strategic adviser through September 30, 2026.
- **2026-07** — Holly Springs selected for FDA PreCheck pilot; expansion target accelerated six months to late FY2027, with a drug product line planned for early 2027 followed by finished goods.
- **2026-04** — Opened a quality-control laboratory in Denmark, doubling the site’s quality-control footprint according to the company.
- **2026-03** — Introduced ShunzymeX purification technology.
- **2026-02** — Opened expanded biomanufacturing and process development facilities in Teesside, UK.

## Links

- Website: https://fujifilmbiotechnologies.fujifilm.com/
- LinkedIn: https://www.linkedin.com/company/fujifilm-biotechnologies
- Twitter/X: https://x.com/FujifilmDiosyn
- Facebook: https://www.facebook.com/fujifilmdiosynth

---

Profile page: https://yespress.io/fujifilm-biotechnologies
Published by YesPress — https://yespress.io
Last updated: 2026-10-22